Cancer Research and Treatment

Do Hyun Nam

4 Articles

Mouse Orthotopic Lung Cancer Model Induced by PC14PE6: Zheng Yun Cui, Jin Seok Ahn, Jee Yun Lee, Won Seog Kim, Ho Yeong Lim, Hyun Jung Jeon, Soo Won Suh, Jin Hoon Kim, Won Ho Kong, Ji Min Kang, Do Hyun Nam, Keunchil Park; Cancer Res Treat. 2006;38(4):234-239. Published online December 31, 2006; DOI: https://doi.org/10.4143/crt.2006.38.4.234

Purpose

This study was undertaken to investigate in detail the xenograft mouse orthotopic lung cancer model induced by PC14PE6 adenocarcinoma cells.

Materials and Methods

Three cell doses (0.5×10⁶; 1×10⁶; 2×10⁶) of PC14PE6 cells were injected into the lungs of male BALB/c nude mice by the intrathoracic injection method. The lung and other organs, including brain, liver, spleen, kidney, muscle, adrenal gland, and lymph node on knee, were removed and stained with H/E to detect the presence of tumor cells.

Results

The reliable tumorigenicity time in the PC14PE6 adenocarcinoma cell-inoculated BALB/c nude mouse was 10 days after intrathoracic injection. The average life span of the three groups after inoculation was 14 days in the 2×10⁶ cells inoculum group; 25 days in the 1×10⁶ cells inoculum group; and 32 days in the 0.5×10⁶ cells inoculum group. The PC14PE6 adenocarcinoma cells induced orthotopic lung cancer limited within the thorax.

Conclusions

This orthotopic lung cancer model is an efficient cancer model with easy inoculation methods, rapid and high tumorigenicity, and simple monitoring methods for metastasis.

Citations

Citations to this article as recorded by

Actin-Dependent Mechanism of Tumor Progression Induced by a Dysfunction of p53 Tumor Suppressor
Natalia Khromova, Maria Vasileva, Vera Dugina, Dmitry Kudlay, Peter Chumakov, Sergei Boichuk, Pavel Kopnin
Cancers.2024; 16(6): 1123. CrossRef
Immuno-PET Imaging of EGFR with 64Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts
Nasim Sarrami, Melinda Wuest, Igor Moura de Paiva, Samantha Leier, Afsaneh Lavasanifar, Frank Wuest
Molecular Pharmaceutics.2024; 21(11): 5797. CrossRef
Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand
M. Isabel Acuña, Ana R. Rubio, Marta Martínez-Alonso, Natalia Busto, Ana María Rodríguez, Nerea Davila-Ferreira, Carl Smythe, Gustavo Espino, Begoña García, Fernando Domínguez
Cancers.2022; 15(1): 107. CrossRef
Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment
Ulrich Jarry, Mégane Bostoën, Raphaël Pineau, Laura Chaillot, Valentine Mennessier, Pierre Montagne, Emilie Motte, Marjorie Gournay, Arnaud Le Goff, Thierry Guillaudeux, Rémy Pedeux
BMC Cancer.2021;[Epub] CrossRef
Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach
Hor-Yue Tan, Venice Wing-Tung Ho, Yau-Tuen Chan, Cheng Zhang, Ning Wang, Wen Xia, Yibin Feng
Pharmacological Research.2020; 155: 104415. CrossRef
Metastatic Spread from Abdominal Tumor Cells to Parathymic Lymph Nodes
Gábor Király, Zoltán Hargitai, Ilona Kovács, Gábor Szemán-Nagy, István Juhász, Gáspár Bánfalvi
Pathology & Oncology Research.2019; 25(2): 625. CrossRef
LPP inhibits collective cell migration during lung cancer dissemination
S Kuriyama, M Yoshida, S Yano, N Aiba, T Kohno, Y Minamiya, A Goto, M Tanaka
Oncogene.2016; 35(8): 952. CrossRef
Docetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancer
Erea Borrajo, Raquel Abellan-Pose, Atenea Soto, Marcos Garcia-Fuentes, Noemi Csaba, Maria J. Alonso, Anxo Vidal
Journal of Controlled Release.2016; 238: 263. CrossRef
Targeting p300 Addiction inCBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation ofMYCExpression
Hideaki Ogiwara, Mariko Sasaki, Takafumi Mitachi, Takahiro Oike, Saito Higuchi, Yuichi Tominaga, Takashi Kohno
Cancer Discovery.2016; 6(4): 430. CrossRef
Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice
T. Jaroensong, Y. Endo, S.‐J. Lee, A. Kamida, M. Mochizuki, R. Nishimura, N. Sasaki, T. Nakagawa
Veterinary and Comparative Oncology.2012; 10(4): 274. CrossRef
A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer
Bo Li, Artour Torossian, Wenyan Li, Stephen Schleicher, Kathy Niu, Nicholas J. Giacalone, Sung June Kim, Heidi Chen, Adriana Gonzalez, Luigi Moretti, Bo Lu
Radiation Research.2011; 176(4): 486. CrossRef
Small Azurin Derived Peptide Targets Ephrin Receptors for Radiotherapy
Ewa D. Micewicz, Chun-Ling Jung, Dorthe Schaue, Hai Luong, William H. McBride, Piotr Ruchala
International Journal of Peptide Research and Therapeutics.2011; 17(3): 247. CrossRef
The Incidence Rate and Severity of Orthotopic Lung Cancer in an Animal Model Depends on the Number of A549 Cells and Transplantation Period
Jinsoo Lee, Young-Ah Han, Hyo-Seon Yang, Jeong-Ah Song, Young-Su Yang, Soonjin Kwon, Min-Sung Kang, Kyuhong Lee, Jeong-Doo Heo, Kyu-Hyuk Cho, Chang Woo Song
Laboratory Animal Research.2010; 26(4): 369. CrossRef
Tumorigenesis after Injection of Lung Cancer Cell Line (SW-900 G IV) into the Pleural Cavity of Nude Mice
Eok-Sung Park, Song-Myung Kim, Jong-In Kim
The Korean Journal of Thoracic and Cardiovascular Surgery.2010; 43(6): 588. CrossRef
Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model
Zheng Yun Cui, Min Jae Park, Jeeyun Lee, Jin Seok Ahn, Myung Ju Ahn, Soo Won Seo, Jin Woo Park, Youngro Byun, Keunchil Park
Cancer Research and Treatment.2009; 41(2): 80. CrossRef

16,097 View
126 Download
15 Crossref

Combined Chemotherapy and Radiotherapy for Primary CNS Lymphoma: Jeong Eun Lee, Dae Yong Kim, Yong Chan Ahn, Do Hoon Lim, Seung Jae Huh, Seong Soo Shin, Won Seok Kim, Won Ki Kang, Do Hyun Nam, Jung Il Lee, Jong Hyun Kim; Cancer Res Treat. 2001;33(5):398-403. Published online October 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.5.398

Abstract PDF: PURPOSE
This study was performed in order to evaluate the effectiveness of combined chemotherapy and radiotherapy (RT) in primary central nervous system lymphoma (PCNSL).
MATERIALS AND METHODS
From January 1995 to August 1999, 21 patients with a diagnosis of PCNSL were treated with combined chemotherapy and radiotherapy. Their median age was 47 years with range of 19 to 78 years. Twelve patients were male and nine patients were female. All patients were immunocompetent and they had no evidence of systemic lymphoma. All patients underwent placement of an Ommaya reservoir and recieved a combination regimen using pre-RT systemic and intra-Ommaya methotrexate (MTX), 40 Gy whole-brain RT with a 14.4 Gy boost, and 2 courses of post-RT high-dose cytarabine. The median follow-up period of all patients and survived patients were 22 months and 36 months, respectively.
RESULTS
The median overall survival duration was 21 months and the overall two- and four-year survival rates were 51% and 43%, respectively. Complete response (CR), partial response, stable disease, and progressive disease were achieved in 12, 3, 1, and 5 patients, respectively. All nine patients without CR expired within 1-31 months (median 6 months). Two patients among the patients with CR developed recurrence after 13 and 14 months, respectively. The location of recurrent disease was within the port of radiation boost. Survival was influenced by age, performance status, and CR. There was one episode of MTX neurotoxicity and hepatotoxicity,respectively.
CONCLUSION
Combined chemotherapy and radiotherapy was an effective treatment for PCNSL, and was associated with a minimum toxicity. However, we must pay attention to the recurrence and late toxicity, particularly within two years following treatment.

4,628 View
38 Download

Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for Intracranial Schwannoma: Dae Yong Kim, Yong Chan Ahn, Jung Il Lee, Do Hyun Nam, Jeong Eun Lee, Do Hoon Lim, Inhwan J Yeo, Seung Jae Huh, Young Joo Noh, Hyung Jin Shin, Kwan Park, Jong Hyun Kim; J Korean Cancer Assoc. 2001;33(1):27-33.

Abstract PDF: PURPOSE
To assess the radiologic response and cranial nerve morbidity in intracranial schwannoma patients treated with stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT).
MATERIALS AND METHODS
Twenty-six patients with intracranial schwannoma were treated with linear accelerator- based SRS or FSRT between February 1995 and October 1999. The origin of schwannoma was acoustic nerve in twenty-one patients, facial nerve in two, trigeminal nerve in two, and glossopharyngeal nerve in one. SRS were performed with the median peripheral dose of 14 Gy (range 12-16), and FSRT were done with the median peripheral dose of 25 2 Gy (range 50-60).
RESULTS
With a median follow-up period of 33 months (range 12-67), the local control rate was 100%. Tumorregression was noted in eleven patients, and tumor stabilization was found in the remaining fifteen. Useful hearing preservation was achieved in two of three patients. Facial nerve neuropathy was shown in two patients and one patients developed trigeminal nerve neuropathy.
CONCLUSION
Stereotactic radiotherapy including SRS and FSRT provided excellent local control in intracranial schwannoma. It shows the possibility of a high rate of hearing preservation and an acceptable neurotoxicity, although the number of patients are small and follow-up is relatively short.

3,445 View
23 Download

Stereotactic Radiotherapy for the Treatment of Brain Metastases: Dae Yong Kim, Yong Chan Ahn, Seung Jae Huh, Jung Il Lee, Do Hyun Nam, Seung Chyul Hong, Hyung Jin Shin, Kwan Park, Jong Hyun Kim; J Korean Cancer Assoc. 2000;32(1):148-155.

Abstract PDF: PURPOSE
To evaluate the clinical results of stereotactic radiosurgery (SRS) and frac- tionated stereotactic radiotherapy (FSRT) for metastatic brain tumors.
MATERIALS AND METHODS
Nineteen patients with brain metastases (34 lesions) were treated with LINAC-based SRS or FSRT with or without whole brain radiotherapy between October 1995 and February 1998. SRS was preferred to FSRT in cases with three or more lesions and poor performance status. FSRT was preferred to SRS in cases with lesions larger than 3 cm and lesions located near or at the eloquent areas such as thalamus, brain stem, and optic apparatus. Single isocenter was used both in SRS and FSRT, and the median peripheral dose in SRS was 15 Gy (range 13~20 Gy), while that in FSRT was 21 Gy (range 15~24 Gy) by 3 Gy per fraction.
RESULTS
Local control was achieved in 79% (27/34 treated lesions) and 1-year over- all survival rate was 58% with the median survival of 12 months. Lethal progressive brain metastases, both local and regional, were in four patients (27% of all deaths). No significant differences in local control and survival was observed with histology, age, sex, performance status, tumor volume, number of lesions, or treatment modality. Unacceptable acute or late complications did not occur.
CONCLUSION
Stereotactic radiotherapy including SRS and FSRT is effective, non-invasive therapy for brain metastases. This study suggests that stereotactic radiotherapy might be an alternative to surgical resection in selected patients of brain metastases.

3,823 View
24 Download

Author index